Clinical Trials on Myositis, Juvenile in Japan

Total 55 results

Daiichi Sankyo Co., Ltd.

Completed

Study of Single-Ascending Doses of DS-6016a in Healthy Japanese Subjects

Fibrodysplasia Ossificans Progressiva

Japan
Bristol-Myers Squibb

Completed

Trial to Evaluate the Efficacy and Safety of Abatacept in Combination With Standard Therapy Compared to Standard Therapy Alone in Improving Disease Activity in Adults With Active Idiopathic Inflammatory Myopathy

Dermatomyositis | Polymyositis | Autoimmune Necrotizing Myopathy | Overlap Myositis | Juvenile Myositis Above the Age of 18

France, United States, Australia, Brazil, Czechia, Germany, Italy, Japan, Korea, Republic of, Mexico, Sweden
Pfizer

Completed

Enbrel-Juvenile Idiopathic Arthritis (JIA) Use Results Survey [All-Case Surveillance] (Enbrel-JIA)

Juvenile Idiopathic Arthritis

Japan
Novartis Pharmaceuticals

Completed

Study of Efficacy and Safety of Canakinumab in Japanese Patients With SJIA

Systemic Juvenile Idiopathic Arthritis

Japan
Japan Blood Products Organization

Completed

Efficacy and Safety Study of GB-0998 for Treatment of Steroid-resistant Polymyositis and Dermatomyositis (PM/DM)

Dermatomyositis | Polymyositis

Japan
Novartis Pharmaceuticals

Completed

An Extension Study of the Efficacy, Safety and Tolerability of BYM338 (Bimagrumab) in Patients With Sporadic Inclusion Body Myositis Who Previously Participated in the Core Study CBYM338B2203

Sporadic Inclusion Body Myositis

United States, Belgium, Italy, Australia, Netherlands, Switzerland, France, United Kingdom, Denmark, Japan
Abbott
Eisai Co., Ltd.

Completed

Safety, Efficacy, and Pharmacokinetics of Adalimumab in Japanese Children With Juvenile Rheumatoid Arthritis

Juvenile Rheumatoid Arthritis

Japan
Clementia Pharmaceuticals Inc.
Ipsen

Recruiting

A Study to Assess the Effectiveness and Safety of 2 Dosage Regimens of Oral Fidrisertib (IPN60130) for the Treatment of Fibrodysplasia Ossificans Progressiva (FOP). (FALKON)

Fibrodysplasia Ossificans Progressiva

United States, Korea, Republic of, Belgium, China, Sweden, France, Japan, Australia, Argentina, Brazil, Canada, Italy, Spain, United Kingdom, Mexico, Colombia, Netherlands, Germany, Portugal
Novartis Pharmaceuticals

Completed

Efficacy and Safety of Bimagrumab/BYM338 at 52 Weeks on Physical Function, Muscle Strength, Mobility in sIBM Patients (RESILIENT)

Sporadic Inclusion Body Myositis

United States, Belgium, Italy, Australia, Netherlands, Switzerland, France, United Kingdom, Denmark, Japan
Comprehensive Support Project for Oncology Research
Novartis Pharmaceuticals

Completed

Evaluation of Oral Care to Prevent Oral Mucositis in ER Positive MBC Patients Treated With Everolimus: Phase 3 RCT

Breast Cancer

Japan
Regeneron Pharmaceuticals

Recruiting

A Study to Assess Safety, Tolerability and Efficacy of Garetosmab Versus Placebo Administered Intravenously (IV) in Adult Participants With Fibrodysplasia Ossificans Progressiva (FOP) (OPTIMA)

Fibrodysplasia Ossificans Progressiva

Japan, United States, Korea, Republic of, Spain, France, Australia, United Kingdom, China, Poland, Malaysia, Italy, Finland, Hong Kong, South Africa, Chile, Brazil, Netherlands, Colombia
Clementia Pharmaceuticals Inc.

Completed

An Efficacy and Safety Study of Palovarotene for the Treatment of Fibrodysplasia Ossificans Progressiva. (MOVE)

Fibrodysplasia Ossificans Progressiva

United States, Canada, France, Australia, Argentina, Brazil, Italy, Japan, Spain, Sweden, United Kingdom
AbbVie

Recruiting

Study of Oral Upadacitinib and Subcutaneous/Intravenous Tocilizumab to Evaluate Change in Disease Activity, Adverse Events and How Drug Moves Through the Body of Pediatric and Adolescent Participants With Active Systemic Juvenile Idiopathic Arthritis. (SELECT-sJIA)

Juvenile Idiopathic Arthritis

United States, Japan, Turkey, Australia, China, Spain, Italy, Germany, Brazil, United Kingdom
Bristol-Myers Squibb
Ono Pharmaceutical Co. Ltd

Completed

Efficacy, Safety, Pharmacokinetics and Immunogenicity Study of Abatacept Administered Intravenously to Treat Active Polyarticular-course Juvenile Idiopathic Arthritis in Japan

Juvenile Idiopathic Arthritis

Japan
AbbVie

Active, not recruiting

A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Upadacitinib in Pediatric Subjects With Polyarticular Course Juvenile Idiopathic Arthritis (SELECT-YOUTH)

Juvenile Idiopathic Arthritis (JIA)

United States, Canada, Germany, Hungary, Israel, Italy, Japan, Puerto Rico, Spain, Sweden
Otsuka Pharmaceutical Co., Ltd.

Completed

A Phase 2 Trial of Rebamipide Liquid to Determine the Effective Dose for Prevention of Chemoradiotherapy-induced Oral Mucositis in Patients With Head and Neck Cancer

Head and Neck Cancer

Japan
Nihon Pharmaceutical Co., Ltd

Completed

Phase II Clinical Trial of NPB-01 in Patients With Anti-aquaporin 4 Antibody Positive Neuromyelitis Optica Spectrum Disorder Not Provided Adequate Effect of Therapy to Steroids Plus Therapy.

Neuromyelitis Optica Spectrum Disorder

Japan
Eli Lilly and Company

Recruiting

A Study of Baricitinib (LY3009104) in Participants From 1 Year to Less Than 18 Years Old With Systemic Juvenile Idiopathic Arthritis (sJIA)

Systemic Juvenile Idiopathic Arthritis

Belgium, Spain, India, Italy, Czechia, Japan, Austria, France, United Kingdom, Brazil, Mexico, Israel, Poland, Argentina, Denmark, Turkey
Swedish Orphan Biovitrum
CMIC Co, Ltd. Japan

Recruiting

A Study of Anakinra in Japanese Patients With Still's Disease (SJIA and AOSD)

Still's Disease, Adult-Onset | Still's Disease, Juvenile Onset

Japan
Sanofi Pasteur, a Sanofi Company

Completed

Study of IMOVAX POLIO® Subcutaneous as a Booster Vaccine in Pre-school Age Children in Japan

Poliomyelitis | Polio

Japan
Janssen Pharmaceutical K.K.

Terminated

A Study of Ustekinumab in Participants With Active Polymyositis and Dermatomyositis Who Have Not Adequately Responded to One or More Standard-of-care Treatments

Dermatomyositis | Polymyositis

Japan
Novartis Pharmaceuticals

Terminated

Safety and Efficacy of BAF312 in Dermatomyositis

Active Dermatomyositis

United States, Czechia, Japan
Eli Lilly and Company

Recruiting

A Study of Baricitinib in Participants From 1 Year to Less Than 18 Years Old With Juvenile Idiopathic Arthritis (JUVE-X)

Juvenile Idiopathic Arthritis

Belgium, Spain, Australia, India, Japan, Italy, Czechia, Austria, France, United Kingdom, Mexico, Israel, Brazil, China, Denmark, Germany, Poland, Russian Federation, Argentina, Turkey
Astellas Pharma Inc

Completed

A Survey for Long-term Use of Prograf Capsules in Patient With Interstitial Pneumonia

Interstitial Pneumonia Associated With Polymyositis/Dermatomyositis

Japan
Eli Lilly and Company

Completed

A Study of Baricitinib in Participants From 2 Years to Less Than 18 Years Old With Juvenile Idiopathic Arthritis (JUVE-BASIS)

Juvenile Idiopathic Arthritis

Spain, India, Israel, Japan, Australia, Belgium, Turkey, Mexico, Italy, Germany, Czechia, United Kingdom, China, Russian Federation, Poland, Brazil, France, Austria, Argentina, Denmark
Janssen Research & Development, LLC

Recruiting

A Study of Nipocalimab in Participants With Active Idiopathic Inflammatory Myopathies (SPIREA)

Myositis

United States, Korea, Republic of, Italy, United Kingdom, Hungary, Spain, Japan, Czechia, France, Mexico, Germany, Canada, Poland
Boehringer Ingelheim

Completed

Volasertib in Combination With Azacitidine in Japanese Patients With Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia

Myelodysplastic Syndromes | Leukemia, Myelomonocytic, Chronic

Japan
Sanofi Pasteur, a Sanofi Company

Completed

Study of SP059 Given Subcutaneously as a Three-dose Primary and Booster Vaccination in Infants in Japan

Poliomyelitis | Polio

Japan
Celgene Corporation

Terminated

Phase 1 Study of CC-486 in Japanese Subjects With Hematological Neoplasms

Acute Myeloid Leukemia | Myelodysplastic Syndromes | Multiple Myeloma | Hodgkin Lymphoma | Chronic Myelomonocytic Leukemia | Non-Hodgkin Lymphoma

Japan
Tokyo Medical and Dental University
Astellas Pharma Inc; Japan Medical Association

Completed

Investigation in Myositis-associated Pneumonitis of Prednisolone And Concomitant Tacrolimus (IMPPACT)

Dermatomyositis | Polymyositis | Interstitial Pneumonitis

Japan
St. Marianna University School of Medicine

Unknown

Efficacy and Safety of Tamibarotene(AM80H) for HTLV-1 Associated Myelopathy/ Tropical Spastic Paraparesis (HAM/TSP)

HTLV-I-Associated Myelopathy

Japan
Mitsubishi Tanabe Pharma Corporation

Completed

A Clinical Pharmacological Study of MT-3921 in Subjects With HTLV-1 Associated Myelopathy (HAM)

HTLV-1-Associated Myelopathy (HAM)

Japan
Alexion Pharmaceuticals, Inc.

Terminated

Ravulizumab Versus Placebo in Adult Participants With Dermatomyositis

Dermatomyositis

Italy, Spain, United States, France, Germany, Korea, Republic of, United Kingdom, Poland, Japan
Corbus Pharmaceuticals Inc.

Completed

Trial to Evaluate Efficacy and Safety of Lenabasum in Dermatomyositis (DETERMINE)

Dermatomyositis

United States, Korea, Republic of, Japan, Spain, United Kingdom, Germany, Hungary, Bulgaria, Canada, Czechia, Italy, Poland, Sweden
Mitsubishi Tanabe Pharma Corporation
The Research Foundation for Microbial Diseases of Osaka University

Completed

Confirmatory Study of BK1310 in Healthy Infants

Pertussis | Tetanus | Diphtheria | Bacterial Meningitis | Poliomyelitis

Japan
CSL Behring

Active, not recruiting

A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of IgPro20 in Adults With Dermatomyositis (DM) (RECLAIIM)

Dermatomyositis

United States, Argentina, Belgium, France, Germany, Hungary, Italy, Japan, Mexico, Poland, Russian Federation, Spain, Switzerland, Ukraine
Novartis Pharmaceuticals

Completed

A Phase Ib Study of Panobinostat (LBH589) in Combination With 5-Azacitidine for Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML) or Acute Myeloid Leukemia (AML) Patients

Myelodysplastic Syndromes (MDS) | Acute Myeloid Leukemia (AML) | Chronic Myelomonocytic Leukemia (CMML)

Japan
Pfizer

Recruiting

A Study to Understand How the Study Medicine (PF-06823859) Works in People With Active Idiopathic Inflammatory Myopathies [Dermatomyositis (DM) and Polymyositis (PM)]

Myositis

China, United States, Japan, Korea, Republic of, Taiwan, Spain, Germany, Hungary, Argentina, Poland, Italy, Bulgaria, India, Belgium, France, Slovakia
Hoffmann-La Roche
Chugai Pharmaceutical Co.

Terminated

A Study In Neuromyelitis Optica Spectrum Disorder (NMOSD) With Satralizumab As An Intervention (SAkuraBonsai)

Neuromyelitis Optica Spectrum Disorder | NMOSD

United States, Korea, Republic of, Italy, Canada, Japan, Turkey
Sanofi Pasteur, a Sanofi Company

Completed

DTaP-IPV/Hib Vaccine Primary & Booster Vaccinations Versus Co-administration of DTaP-IPV and Hib Vaccine in Japanese Infants

Pertussis | Tetanus | Diphtheria | Bacterial Meningitis | Poliomyelitis

Japan
Pfizer

Completed

Continuation Study of B1371019(NCT03416179) and B1371012(NCT02367456) Evaluating Azacitidine With Or Without Glasdegib In Patients With Previously Untreated AML, MDS or CMML

Acute Myeloid Leukemia | Chronic Myelomonocytic Leukemia | Myelodysplastic Syndrome

Spain, Canada, Austria, Czechia, France, Hungary, Italy, Japan, Mexico, Poland, United Kingdom
Alexion Pharmaceuticals, Inc.

Completed

A Phase 3 Open-Label Study of Eculizumab in Pediatric Participants With Refractory Generalized Myasthenia Gravis (gMG)

Myasthenia Gravis | Myasthenia Gravis, Generalized | Myasthenia Gravis, Juvenile Form

United States, Japan, Netherlands
Chugai Pharmaceutical

Not yet recruiting

Phase 1b Trial of RAY121 in Immunological Diseases (RAINBOW Trial)

Antiphospholipid Syndrome (APS) | Immune Thrombocytopenia (ITP) | Dermatomyositis (DM) | Bullous Pemphigoid (BP) | Behçet's Syndrome (BS) | Immune-mediated Necrotizing Myopathy (IMNM)

United States, Japan
Alexion Pharmaceuticals, Inc.

Recruiting

Efficacy and Safety Study of Ravulizumab IV in Pediatric Participants With NMOSD

Neuromyelitis Optica Spectrum Disorder

United States, Italy, Korea, Republic of, Japan, France, Germany, Spain, Canada
Kyowa Kirin Co., Ltd.

Terminated

A Study of KW-0761 in Subjects With HTLV-1 Associated Myelopathy (HAM)

HTLV-1 Associated Myelopathy

Japan
Alexion Pharmaceuticals, Inc.

Terminated

A Study of the Safety and Activity of Eculizumab in Pediatric Participants With Relapsing Neuromyelitis Optica Spectrum Disorder

Neuromyelitis Optica | Neuromyelitis Optica Spectrum Disorder

United States, Italy, Canada, Japan, Spain, Korea, Republic of, Germany
Hoffmann-La Roche
Chugai Pharmaceutical

Completed

Efficacy and Safety Study of Satralizumab (SA237) as Add-on Therapy to Treat Participants With Neuromyelitis Optica (NMO) and NMO Spectrum Disorder (NMOSD)

Neuromyelitis Optica (NMO) | NMO Spectrum Disorder (NMOSD)

Spain, Italy, United States, Japan, Poland, Taiwan, Germany, United Kingdom, Hungary, France, Ukraine
Hoffmann-La Roche

Active, not recruiting

A Study to Evaluate the Safety and Efficacy of Satralizumab in Participants With Neuromyelitis Optica Spectrum Disorder (NMOSD)

Neuromyelitis Optica Spectrum Disorder

United States, Spain, United Kingdom, Taiwan, Hungary, Korea, Republic of, Japan, Croatia, Bulgaria, Canada, Germany, Italy, Poland, Puerto Rico, Romania, Turkey, Ukraine, Malaysia
Experimental and Clinical Research Center, a cooperation...

Recruiting

Acute Optic Neuritis Network: an International Study That Invesitages Subjects With a First-ever Episode of Acute Inflammation of the Optic Nerve (ACON)

Multiple Sclerosis | Demyelinating Diseases | Optic Neuritis | Neuromyelitis Optica Spectrum Disorder Attack | Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease

Italy, United States, Argentina, Australia, Botswana, Brazil, Colombia, Denmark, France, Germany, India, Israel, Japan, Korea, Republic of, Spain, United Kingdom, Zambia
Novartis Pharmaceuticals

Active, not recruiting

Study of Efficacy and Safety of MBG453 in Combination With Azacitidine in Subjects With Intermediate, High or Very High Risk Myelodysplastic Syndrome (MDS) as Per IPSS-R, or Chronic Myelomonocytic Leukemia-2 (CMML-2) (STIMULUS-MDS2)

Myelodysplastic Syndromes | Leukemia, Myelomonocytic, Chronic

China, Czechia, Japan, Saudi Arabia, Taiwan, Turkey, Germany, Spain, Netherlands, Italy, Singapore, Australia, Austria, France, United Kingdom, Korea, Republic of, Thailand, Israel, Belgium, Canada, Switzerland, Lithuania, Russian Federation and more

Clinical Trials on Myositis, Juvenile in Japan

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Macedonia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations